Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Biotech partnership eyes Euro market expansion for Rett syndrome drug
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
Stocking stuffers: Morgans’ top ASX health picks for 2025
Health & Biotech
Health Check: Clinical trials don’t sleigh down for the silly season
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Health Check: Mayne Pharma and Acrux are on a drug expansion drive, generically speaking
Health & Biotech
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
Health & Biotech
Scott Power: ACCC’s approval of Sigma, Chemist Warehouse union turned heads this week
News
Closing Bell: ASX pops on tech, banks, goldies and possible China ‘bazooka style’ stimulus
News
Closing Bell: ASX swings wildly, Scentre drags and these assets could Trump bump
News
ASX Small Caps Lunch Wrap: Sigma-Chemist merge a done deal; Quickstep kicks up 95pc
Health & Biotech
Health Check: Neuren’s ‘Willy Wonka’ voucher shows how a piece of paper can be worth US$50m
Health & Biotech
Health Check: Rats – and investors – are happy as Nyrada forges ahead with its first human trial
Health & Biotech
ASX stocks leading clinical trials in Australia
Health & Biotech
Australia proves its reputation as ‘go-to’ destination for clinical trials
Health & Biotech
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
News
